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Abstract: Aurora A (AurA) kinase is a key mitotic protein essential for carrying out numerous cellular functions. 
Overexpression or malfunction of this enzyme results in numerous human diseases most notably in cancer.  Several small molecule inhibitors 
targeting the ATP binding site of this enzyme are in various stages of clinical development. However, ATP binding site inhibitors can result 
in selectivity problems often leading to undesirable off-target effects. Moreover, these drugs are prone to drug resistance problem rendering 
them unfit for long-term administration. Allosteric inhibition of kinases using small molecules is an alternative strategy to target these 
enzymes and these could serve as the seeds for next generation medicines and minimize any selectivity problems associated with ATP 
binding site inhibitors. This review discusses the developments in the non-ATP site binding small molecule inhibitors of AurA  and their 
prospect as future therapeutics and tools for chemical biology. 
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1. INTRODUCTION 
      Kinases play a crucial role in signal transduction and 
numerous cellular processes [1, 2]. Aberrant regulation of 
kinases leads to various human diseases. Kinases have been 
targeted to treat a range of diseases such as cancer [3-5], 
diabetes [6, 7], rheumatoid arthritis [8, 9], idiopathic 
pulmonary fibrosis [10], neurological [11, 12], immune 
disorders [13], and even cardiovascular diseases [14].  As of 
September 2016, a total of 33 small molecule inhibitors 
targeting various kinases have been approved by the FDA 
with around 20 of these drugs approved since 2010 [15, 16]. 
This is the testimony of how crucial targeting these enzymes 
are in the present drug discovery arena. The majority of these 
approved drugs target the ATP binding site (active site), 
which is highly conserved within different families of 
kinases [17, 18]. Targeting the ATP binding site of the 
kinases can result in poor selectivity and can cause side-
effects for the patients. In addition, there can be the 
emergence of drug resistance due to kinase active site 
mutation [19, 20]. One way of tackling this problem is by 
designing inhibitor which could binds at a distant allosteric 
site on a kinase and able to arrest the kinase activity. These 
type of inhibitors are referred to as type IV inhibitors [17, 21, 
22]. Unlike the enzyme active site which are characterized 
by deep and hydrophobic pockets, allosteric sites are often  
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shallow pockets which makes them difficult to target using 
small molecules as the interaction area is minimal with small 
molecules unlike the natural protein ligands or peptides [23-
26].  
Generally, kinases possess multiple allosteric sites which 
could be used to bind and interact with different other 
protein partners. Bivalent phage display approach [xx]  and 
in situ screening methods [xx] can be used to identify 
allosteric sites which are close to the active sites of enzymes. 
Targeting distant allosteric sites would be more beneficial in 
coming up with highly selective inhibitors which are less 
prone to resistance problems. Those allosteric sites could be 
identified and targeted by small molecules by two most 
common approaches.  (1) High-throughput screening (HTS) 
of a large library of compounds  and (2) Fragment-based 
approaches. HTS followed by Structure-Activity 
Relationship (SAR) studies remains the most common 
choice to identify allosteric inhibitors. Inhibitors targeting 
the allosteric sites of Mitogen-Activated Protein Kinases 
(MAPK) discovered by this approach  are in various stages 
of clinical trials [27,28]. Fragment-based approaches using 
X-ray crystallography [29] and tethering  are more rational 
ways to identify allosteric ligands. 3-phosphoinositide-
dependent protein kinase-1 (PDK1) has been subjected to 
allosteric inhibition by using disulfide-based tethering 
approach [30]. Recently, computational method [30], 
vibrational spectroscopic technique (discussed in 1.2.2), etc. 
to identify distant allosteric sites are also beginning to 
appear. Apart from MAPK and PDK1 there are only a 
handful of other kinases which have been successfully 
targeted at distant allosteric sites using small molecules, one 
such kinase is Aurora A (AurA). 
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      Aurora Kinases are the family of three Serine/Threonine 
kinases (A, B and C) that play key roles in cell division [31, 
32]. AurA is associated in regulating the early stages of the 
mitosis, which includes centrosome maturation and 
separation, mitotic entry and bipolar spindle formation, and 
has a major role in upholding the genomic integrity of the 
daughter cells [33-38]. AurA is frequently overexpressed in 
diverse human cancers such as breast, pancreatic, ovarian, 
and gastric [39]. It is also known to deregulate a crucial 
tumour suppressor protein p53 [40]. Moreover, 
overexpression of AurA induces resistance to Taxol, a first-
line chemotherapeutic agent [41]. Recently it has been 
suspected that AurA could contribute to glioblastoma tumor 
recurrence [42]. All of the above mentioned factors suggest 
that AurA has potential as an excellent target for cancer 
treatment and necessitates the need for novel therapeutic 
agents to selectively target AurA with fewer off-target 
effects. A number of ATP competitive inhibitors of AurA are 
already in various stages of clinical development [5, 43]. 
However, all these small molecules target the highly 
homologous ATP active site on the kinase and may result in 
selectivity and drug-resistance problems.  Recently, there is 
an interest aimed at targeting allosteric inhibition sites of 
AurA kinase and this review summarizes the small-molecule 
inhibitors which have been developed to target allosteric 
sites of AurA kinase. 
 
1.1. Targeting the AurA-TPX2 interaction: 
 
      Allosteric sites on kinases are often used for interacting 
with other protein partners, and by targeting these, selective 
modulation of the kinases could be achieved [16, 22].  AurA 
kinase is known to bind and interact with various protein 
partners to carry out its cellular functions. Among them the 
interaction with Targeting Protein for Xenopus kinesin-like 
protein 2 (TPX2) is structurally and biochemically well 
studied [44, 45]. This interaction is crucial for the successful 
mitotic progression. Abolishing TPX2 function in cells 
prevents the localization of AurA to the spindles during 
mitosis and resulted in apoptosis [46]. TPX2 is a larger 
protein than AurA, however, residues 7-43 of TPX2 has 
shown to be adequate for binding and activating AurA [44, 
45, 47]. Residues 7-21 bind at the N-terminal lobe of AurA 
and responsible for anchoring the TPX2 mainly through 
hydrophobic interactions whilst TPX2 residues 30-43  
interact with the activation loop of the kinase. Upon TPX2 
binding, AurA attains the active conformation necessary for 
catalysis [44]. Hence by targeting the AurA-TPX2 
interaction using small molecules, one could selectively 
abolish the kinase activity. A number of research groups 
have reported targeting this interaction and these are reviews 
below. 
1.1.1 Lewis' Patent on HTS to identify non-ATP 
competitive AurA inhibitors 
      One of the first high-throughput screening (HTS) 
campaigns to identify non-ATP competitive AurA inhibitors 
was carried out by Lewis and co-workers at EMBL, 
Heidelberg [48]. They identified a  number of non-ATP 
competitive compounds based on aromatic amides and urea 
derivatives capable of inhibiting the AurA kinase activity 
both in vitro and in HeLa cells, and one of those compounds 
was validated by TPX2 competition assay to bind at the 
TPX2 binding site on AurA kinase.  
      In their study, a commercial library of 53,000 
compounds were screened for Aur A kinase activity. 
Standard luciferase assay for measuring kinase activity was 
employed to find out the active compounds [49]. The active 
compounds identified in the screening were then subjected to 
a commercial Z'Lyte Kinase™ assay (a Fluorescence 
Resonance Energy Transfer-based biochemical assay) to 
ascertain if they were ATP competitive. Dose-response 
experiments were performed and the IC50 values for the 
active compounds were measured at 3 different ATP 
concentrations of 20, 200 and 1000 µM. The criterion that 
set was if the IC50 value of the compound increased by more 
than 5 folds per log10 increase in ATP concentration, then 
the particular compound was considered to be ATP 
competitive. Four compounds (compounds 1 to 4) were 
identified to disobey this criteria and were considered to be 
non-competitive with ATP (Fig. 1). Three out of these four 
compounds posses a common 4,4'-bipyridine scaffold 
(compounds 1, 2 and 3) with a urea linkage whilst the last hit 
was a nicotinoyl derivative with amide linkages (compound 
4). Data for compound 3 showed that the IC50 values 
remained almost unchanged even at 1000 µM concentration 
of ATP. The next step to determine where these compounds 
were binding was to perform a competition assay with 
recombinant TPX2 protein which was carried out to 
ascertain if the ATP non-competitive compounds bind at 
TPX2 binding site on AurA. Compound 1 was found to 
compete with TPX2 recombinant peptide in the competition 
assay where it's IC50 value increased from 4.8 µM (in the  
Fig. (1). Non-ATP competitive AurA inhibitors 
 
absence of recombinant TPX2) to 78.8 µM (in the presence 
of recombinant TPX2) suggesting that the compound is 
competing with TPX2 and could be binding at the TPX2 
binding site on the AurA. Furthermore, in a cell-based assay 
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compounds (1-4) were shown to inhibit cell proliferation by 
inhibiting AurA kinase activity. All the 4 compounds were 
showing IC50 of low µM values in HeLa cells. From this 
study, the 4 compounds (1- 4) identified were shown to be 
ATP non-competitive and could abolish AurA kinase 
activity but their binding site is still unclear due to the lack 
of any X-ray crystal structure data of the protein-inhibitor 
complex.  
1.1.2 Conti's Patent on computational modeling of 
allosteric AurA inhibitors 
      Conti, Bayliss and co-workers were the first to disclose 
the X-ray crystal structures of the phosphorylated human 
AurA fragment  (122-403) and also with a ligand bound 
(human TPX2 residues 1-43). They were among the pioneers 
to elucidate the structural basis of AurA activation by 
TPX(1-43) peptide [44]. In a patent, based on the X-ray 
crystal structures and using computational modeling studies, 
they have designed compounds with the aim of allosteric 
inhibition of AurA kinase [50]. They have shown a few 
indole and indene derived compounds could act as inhibitors 
of AurA kinase and claim that these compounds induces 
conformational change on the protein and therefore 
decreasing the kinase activity. Further they claim that some 
of these molecules or at least a portion of the molecules bind 
with one or more residues on the TPX2 binding region on 
AurA (Fig. 2). However no crystal structure of these small 
molecules- AurA complexes were reported and have not 
been deposited in the PDB. In a cell based assay the indoles 
5 and 6 are specific towards Aurora Kinase and it does not 
interfere with the activities of Protein Kinase A (PKA). 
Conversely, other than PKA the effect of these small 
molecules on the activities of other kinases were not 
compared. 
Fig. (2). Non-competitive AurA inhibitors designed based on 
modeling 
1.1.3 Cambridge work on AurA-TPX2 inhibitors 
      A team of research groups at the University of 
Cambridge has successfully developed inhibitors of the 
protein-protein interaction between AurA and TPX2(1-43) 
peptide [51]. The compounds inhibit AurA activity by a 
novel mechanism as elucidated by crystal structures, in vitro 
and in vivo assays. A library of 170,000 rationally selected 
compounds [52] was screened in order to identify novel PPI 
inhibitors between the AurA and TPX2 interaction using an 
in-house developed FP assay. The assay made use of 
TAMRA-labeled TPX2(1-43) peptide which binds with a Kd 
of 8 nM to AurA(123-403) segment in fluorescence 
anisotropy assay. Fifteen compounds were found as hits and 
in order to make sure that the compounds are ATP non-
competitive, the screening was performed by blocking the 
ATP-site of the kinase using a potent non-selective kinase 
inhibitor JNJ-7706621 (JNJ) [53]. JNJ does not affect the 
binding of TPX2(1-43) peptide and stabilizes AurA. It was 
found that various hit compounds were able to bind with 
AurA even in the presence of excess JNJ suggesting that the 
compounds are non-ATP competitive. Compound 7 was 
identified to be the most promising hit with a ligand 
efficiency (LEff) of 0.25 and a Kd of 10.6 µM (ITC) with 
AurA  which was in line with Ki of 8.9 µM determined in FP 
assay (Fig. 3). A brief SAR study was carried out by 
modification of the substituents on the quinoline ring in 
compound 7 and from the study the team identified 
compound 8 to be more ligand efficient (LEff = 0.36) and 
potent compound with a Kd  of 3.77 µM (ITC).  
      A X-ray crystal structure of the ligand-protein complex is 
the gold standard for pinpointing the binding site of the 
ligand with the protein. The Cambridge team is the first to 
obtain and publish the X-ray crystal structure of TPX2 site 
inhibitor-AurA complex (2.05 Ǻ - 2.86 Ǻ). The X-ray crystal 
structure revealed compound 8 was positioned inside a 
hydrophobic pocket (termed as 'Y' pocket) on AurA where 
the two tyrosine residues in the YSY motif (Y = Tyrosine, S 
= Serine) of TPX2 binds. The binding of the ligand is 
characterized by the interaction of the quinoline unit and 
phenyl ring which form hydrophobic interaction in the so 
called 'Y'-pocket as defined by residues L178, V182, V206 
and L208. The bromine substituent on the phenyl ring helped 
to reinforce the contact . Further, the carboxylic acid group 
on compound 8 is engaged in ionic interaction with K166 
and H201. The binding of the ligand induced local 
conformational changes to the protein with the electron 
density of the activation loop remain largely undefined. The 
αC helix and the glycine rich G-loop also changed 
conformation and it should be noted that this loop plays key 
roles in AurA  kinsase activity. In the in vitro kinase assays, 
compound 8 showed a dose dependent inhibition of the 
kinase activity with a Ki of 3.7 µM. The kinetic profile 
showed that the Km value of ATP remained unchanged 
suggesting an allosteric mode of inhibition. In cell based 
assay compound 8 caused mislocalisation of AurA from the 
bipolar spindle and also resulted in decreased T288 
phosphorylation - an indication of decreased AurA activity. 
All the above results clearly suggest that the  'Y' pocket is 
indeed druggable and inhibitors targeting this site may 
allosterically inhibit the kinase activity by a novel 
mechanism opening up new avenues for specifically 
targeting AurA. 
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Fig. (3). Work from the Cambridge group (a) Structures of AurA-
TPX2 inhibitors identified by the Cambridge group. (b) Crystal 
structure of the Y-pocket of AurA showing the binding of AurkinA 
(blue) overlayed with TPX2(8-11) fragment (orange) (c)  
Interactions of AurkinA in the Y-pocket of AurA [Figures (3b) and 
(3c) were reprinted from Scientific Reports, DOI: 
10.1038/srep28528 which has been distributed under a Creative 
Commons CC-BY license] 
1.2. Other Allosteric modulators of AurA 
 
      Apart from TPX2 protein, AurA binds and gets activated 
by various other protein partners such as Ajuba [54], Bora 
[55], N-Myc [55a], etc. This provide opportunities to design 
small molecules which could modulate AurA functions 
selectively. A few selective modulators of  AurA has been 
recently reported and reviews below. 
1.2.1 Anarcardic acid as selective modulator of AurA 
      There has been numerous reports on upstream regulators 
of AurA such as TPX2, Ajuba and Bora which promote 
phosphorylation and increase kinase activity of Aurora 
kinase A (AurA). Kishore and co-workers reported for the 
first time, a small-molecule natural product compound that 
could enhance the activity of Aurora Kinases, specifically 
AurA [56]. They adopted an in silico approach using Hex 4.5 
software to screen natural product compounds from various 
resources. The search led to the finding of Anacardic Acid 
(AA) isolated from the nutshell liquid of Anacardium 
occidentale [57]. Anacardic acid is a salicylic acid derivative  
with an alkyl chain (Fig. 4). The validation of docking 
experiments and the measurement of dose-response 
confirmatory assays were performed by measuring the extent 
of histone H3 phosphorylation by AurA and Aurora kinase B 
(AurB) in the presence or absence of AA. Though AA 
showed interaction with both AurA (amino acid residues 
126-129) and AurB (amino acid residues 142-154) in the 
initial docking studies, it eventually turned out that only 
AurA gets augmentation in activity by 5 fold upon AA 
binding and not AurB.  
      The authors then investigated the detailed mechanistic 
aspects of this specific activity enhancement upon AurA-AA 
interaction. The effect of equilibrium binding of ATP and  
 
Fig. (4). Anacardic acid: Selective modulator of AurA. 
 
AA to AurA was analysed (measuring the association 
constant (Ka) of ATP to AurA in presence of AA and vice 
versa) by spectrofluorometric assays. It was concluded that 
AA induces a structural change in the AurA, which in turn 
enhances the ATP recruitment by the enzyme thereby 
activating the process of phosphorylation. It was also found 
that AA enhances AurA activity by increasing the Vmax of the 
reaction as well (from the kinetic analysis of AA mediated 
activation of AurA). This data and further investigations 
point to AurA kinase activity enhancement is through 
enhancement of autophosphorylation. To conclude, AA 
mediated alteration of enzyme structure and activation of 
autophosphorylation are the underlying mechanisms for 
inducing AurA activity. The role of AurA during mitosis has 
already been defined to a large extent. As AurA is a target 
Br
♦Change in local conformation of AurA
♦Abolishes TPX2 binding
♦Reduced kinase activity
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molecule for the development of antineoplastic drugs that 
attempt to halt cell proliferation, it would be more interesting 
to find out the functional groups of AA responsible for the 
activation of AurA and to establish its further link between 
over-expression of AurA and cancer.  
1.2.2 Felodipine: uncompetitive inhibitor of AurA  
      Karthigeyan and co-workers demonstrated that SERS 
(surface enhanced Raman spectroscopy) could be used as a 
technique to determine the binding site of small molecules 
on the Aurora A protein [58]. SERS is a vibrational 
spectroscopy technique that is highly sensitive where it can 
detect molecules at the single molecule level [59]. This  
technique is widely used in the area of nanotechnology 
however it has only recently been applied to the study of 
both protein-protein and protein-ligand interactions [60-62]. 
 
The authors were interested in the development of a selective 
Aurora A inhibitor by trying to differentiate these from 
Aurora B. They discovered that the drug felodipine could act 
as a selective inhibitor of Aurora A under physiological 
conditions. Felodipine is a dihydropyridine compounds that 
is used as an antihypertensive drug for high blood pressure 
and can inhibit the H3 phosphorylation by Aurora A in a 
dose dependant manner however with negligible effect on 
Aurora B. In order to obtain a suitable SERS spectra citrate 
capped silver nanoparticles were attached to the positive 
charged regions of the kinase proteins by electrostatic 
attraction at physiological pH. A significant change in the 
SERS spectra of Aurora A complexed with felodipine 
compared to that of Aurora B was observed, which was 
attributed to a change in orientation in the Aurora A 
attachment on the silver nanoparticle (Fig. 5). The key peaks 
in the SERS spectrum are from the aromatic amino acids 
Phe, Tyr, His and Trp amide bands. It was hypothesised the 
felodipine was a surface binding ligand and the most 
significant effect observed upon felodipine binding to 
Aurora A was the amide I band which changed from 
1,620cm-1 to 1,647 cm-1. Upon binding of a know Aurora A 
and Aurora B inhibitor, reversine, no change in this amide 
band was observed, however two new peaks were observed 
at 1,297 and 1,369 cm-1 in Aurora A-reversine complex and 
1,293 and 1,376 cm-1 for Aurora B-reversine complex. Under 
competition experiments it was shown that reversine was not 
competitive with felodipine suggesting an alternative binding 
site.  
      These results suggest that the felodipine is binding at a 
new site on Aurora A. In order to confirm this further MD 
simulations and molecular docking suggested that felodipine 
causes a number of conformational changes that lined the 
active site which may affect the ATP binding to Aurora A. 
Further experimental evidence for the binding of felodipine, 
point mutations were carried out on Aurora A and this 
confirmed the binding mechanisms predicted by these 
techniques. The results obtained from SERS, molecular 
docking and MD simulations suggest that felodipine is an 
uncompetitive inhibitor of Aurora A. This study also shows 
that the technique such as SERS can distinguish between 
surface binding and competitive binding of small molecule’s 
of Aurora A kinase. 
 
 
Fig. (5). A: mode of attachment of Aurora A to Ag nanoparticle. B: 
Change in orientation of Aurora A to Ag nanoparticle upon 
complexation with felodipine (red box). 
 
CONCLUSION AND OUTLOOK 
 
      Allosteric inhibition of AurA has been shown to be an 
alternative strategy for inhibition as it is expected to have 
fewer off-target effects when compared with the ATP 
binding site targeting strategies. These allosteric site binding 
inhibitors could prove to be less prone to drug resistance and 
may also find utility in the reversal of taxane resistance, a 
major clinical problem in the cancer treatment. Apart from 
the potential clinical uses, these molecules could act also as 
valuable chemical tools to uncover a wide range of 
biological roles of AurA and its protein partners. New 
techniques such as fragment-based approaches, SERS-
methods are evolving to identify allosteric site binding 
ligands thus overcoming the general difficulties associated 
with the identification of such ligands. Research towards 
allosteric inhibition of AurA is rapidly growing, and 
expected to deliver fruitful outcome in terms of novel 
therapeutics and understanding of the cellular mechanism of 
AurA. This strategy of allosteric-targeting could also be 
amenable to identify selective modulators for other classes of 
therapeutically important protein targets. 
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